424 related articles for article (PubMed ID: 26613512)
21. Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma.
Gu L; Xie L; Zuo C; Ma Z; Zhang Y; Zhu Y; Gao J
BMC Cancer; 2015 Jul; 15():529. PubMed ID: 26189041
[TBL] [Abstract][Full Text] [Related]
22. [Significance of mTOR (mammalian target of rapamycin) activity in human lymphomas].
Márk Á
Magy Onkol; 2014 Jun; 58(2):143-8. PubMed ID: 25010764
[TBL] [Abstract][Full Text] [Related]
23. In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity.
Eleftheriadis T; Pissas G; Sounidaki M; Antoniadi G; Antoniadis N; Liakopoulos V; Stefanidis I
Int Urol Nephrol; 2017 Sep; 49(9):1691-1697. PubMed ID: 28508247
[TBL] [Abstract][Full Text] [Related]
24. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis.
Patsenker E; Schneider V; Ledermann M; Saegesser H; Dorn C; Hellerbrand C; Stickel F
J Hepatol; 2011 Aug; 55(2):388-98. PubMed ID: 21168455
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) Enhances ATP Production in B Cell Tumors through mTOR and HIF-1α.
Incrocci R; Monroy Del Toro R; Devitt G; Salimian M; Braich K; Swanson-Mungerson M
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612754
[TBL] [Abstract][Full Text] [Related]
26. Everolimus: a guide to its use in liver transplantation.
Keating GM; Lyseng-Williamson KA
BioDrugs; 2013 Aug; 27(4):407-11. PubMed ID: 23696253
[TBL] [Abstract][Full Text] [Related]
27. Different in vitro proliferation and cytokine-production inhibition of memory T-cell subsets after calcineurin and mammalian target of rapamycin inhibitors treatment.
Merino D; San Segundo D; Medina JM; Rodrigo E; Asensio E; Irure J; Fernández-Fresnedo G; Arias MA; López-Hoyos M
Immunology; 2016 Jun; 148(2):206-15. PubMed ID: 26931075
[TBL] [Abstract][Full Text] [Related]
28. Oscillatory mTOR inhibition and Treg increase in kidney transplantation.
Sabbatini M; Ruggiero G; Palatucci AT; Rubino V; Federico S; Giovazzino A; Apicella L; Santopaolo M; Matarese G; Galgani M; Terrazzano G
Clin Exp Immunol; 2015 Nov; 182(2):230-40. PubMed ID: 26077103
[TBL] [Abstract][Full Text] [Related]
29. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
[TBL] [Abstract][Full Text] [Related]
30. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity.
Hoerning A; Wilde B; Wang J; Tebbe B; Jing L; Wang X; Jian F; Zhu J; Dolff S; Kribben A; Hoyer PF; Witzke O
Transplantation; 2015 Jan; 99(1):210-9. PubMed ID: 25099702
[TBL] [Abstract][Full Text] [Related]
32. Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation.
Peddi VR; Wiseman A; Chavin K; Slakey D
Transplant Rev (Orlando); 2013 Oct; 27(4):97-107. PubMed ID: 23932018
[TBL] [Abstract][Full Text] [Related]
33. Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus.
Lamoureux F; Picard N; Boussera B; Sauvage FL; Marquet P
Fundam Clin Pharmacol; 2012 Aug; 26(4):463-72. PubMed ID: 21631587
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus, rapamycin, and host immune responses.
Krams SM; Martinez OM
Curr Opin Organ Transplant; 2008 Dec; 13(6):563-8. PubMed ID: 19060543
[TBL] [Abstract][Full Text] [Related]
35. Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease.
Brewin J; Mancao C; Straathof K; Karlsson H; Samarasinghe S; Amrolia PJ; Pule M
Blood; 2009 Nov; 114(23):4792-803. PubMed ID: 19770360
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus associated Burkitt lymphoma in a heart transplant recipient.
Hunt BJ; Thomas JA; Burke M; Walker H; Yacoub M; Crawford DH
Transplantation; 1996 Sep; 62(6):869-72. PubMed ID: 8824493
[TBL] [Abstract][Full Text] [Related]
37. Cyclosporin A inhibits colon cancer cell growth independently of the calcineurin pathway.
Werneck MB; Hottz E; Bozza PT; Viola JP
Cell Cycle; 2012 Nov; 11(21):3997-4008. PubMed ID: 22992618
[TBL] [Abstract][Full Text] [Related]
38. Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12.
van Rossum HH; Romijn FP; Smit NP; de Fijter JW; van Pelt J
Biochem Pharmacol; 2009 Apr; 77(7):1206-12. PubMed ID: 19154728
[TBL] [Abstract][Full Text] [Related]
39. Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.
Sang AX; McPherson MC; Ivison GT; Qu X; Rigdon J; Esquivel CO; Krams SM; Martinez OM
Am J Transplant; 2019 May; 19(5):1305-1314. PubMed ID: 30549430
[TBL] [Abstract][Full Text] [Related]
40. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients.
Havenith SH; Yong SL; van Donselaar-van der Pant KA; van Lier RA; ten Berge IJ; Bemelman FJ
Transplantation; 2013 Jan; 95(1):184-91. PubMed ID: 23222818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
